Tonix Pharmaceuticals (TNXP)
(Delayed Data from NSDQ)
$0.15 USD
0.00 (-1.60%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $0.14 -0.01 (-5.08%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
TNXP 0.15 0.00(-1.60%)
Will TNXP be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for TNXP based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for TNXP
WHO Declares Monkeypox Public Emergency: 5 Mpox Stocks to Watch
TNXP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for TNXP
Tonix Pharmaceuticals files $300M mixed securities shelf
Tonix Pharmaceuticals announces issuance of U.S. patent on Tosymra
New Hope for Mpox? How TNX-801 Could Meet the WHO's Vaccine Targets for a Safer, Single-Dose Solution
Tonix Pharma Advances Promising Mpox Vaccine Candidate
Tonix announces single dose of TNX-801 aligns with WHO Preferred TPP